Superficial Vein Thrombosis
7
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
29%
2 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg
Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein
INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis
Superficial Vein Thrombosis (SVT) Treated With Rivaroxaban Versus Fondaparinux
Novel Strategy to Encourage Early Removal of Central Venous Catheters
Incidence of Superficial Vein Thrombosis